MK2 deletion in mice prevents diabetes-induced perturbations in lipid metabolism and cardiac dysfunction

Diabetes

Volumn 65, Issue 2, 2016, Pages 381-392

  Ruiz, Matthieu ^a,b   Coderre, Lise ^a,b   Lachance, Dominic ^a,b   Houde, Valérie ^a,b   Martel, Cécile ^b   Legault, Julie Thompson ^a,b   Gillis, Marc Antoine ^b   Bouchard, Bertrand ^a,b   Daneault, Caroline ^a,b   Carpentier, André C ^c   Gaestel, Matthias ^d   Allen, Bruce G ^a,b   Des Rosiers, Christine ^a,b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MONTREAL HEART INSTITUTE   (Canada)

^c CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

^d HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 6; FATTY ACID; GLUCOSE REGULATED PROTEIN 78; GLUCOSE TRANSPORTER 1; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; KETONE BODY; MITOGEN ACTIVATED PROTEIN KINASE P38; MYOSIN HEAVY CHAIN BETA; PALMITIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PROTEIN KINASE; PROTEIN KINASE MK2; PROTEIN TYROSINE PHOSPHATASE 1B; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ACYLCARNITINE; CARNITINE; MAP-KINASE-ACTIVATED KINASE 2; PROTEIN SERINE THREONINE KINASE; SIGNAL PEPTIDE; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALORIC INTAKE; CARDIOMYOPATHY; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; ENZYME PHOSPHORYLATION; FATTY ACID OXIDATION; GLUCONEOGENESIS; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLYCOLYSIS; HEART DISEASE; HEART FUNCTION; HEART MUSCLE CONTRACTILITY; HEART MUSCLE METABOLISM; HEART MUSCLE OXYGEN CONSUMPTION; HEART STROKE VOLUME; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID METABOLISM; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY CHAIN; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; CHEMICALLY INDUCED; DIABETIC CARDIOMYOPATHY; EXPERIMENTAL DIABETES MELLITUS; GENE DELETION; GENETICS; METABOLISM; MUSCLE CONTRACTION;

ANIMALS; CARNITINE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC CARDIOMYOPATHIES; FATTY ACIDS, NONESTERIFIED; GENE DELETION; HYPERGLYCEMIA; INSULIN; INSULIN RESISTANCE; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KETONE BODIES; LIPID METABOLISM; MICE; MUSCLE CONTRACTION; PROTEIN-SERINE-THREONINE KINASES; STREPTOZOCIN; TRIGLYCERIDES;

EID: 84962438988     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db15-0238     Document Type: Article

References (50)

1. Harper W, Clement M, Goldenberg R, et al.; Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Pharmacologic management of type 2 diabetes. Can J Diabetes 2013; 37(Suppl. 1): S61-S68
2. Agarwal AA, Jadhav PR, Deshmukh YA. Prescribing pattern and efficacy of anti-diabetic drugs in maintaining optimal glycemic levels in diabetic patients. J Basic Clin Pharm 2014; 5: 79-83
3. Cusi K. The role of adipose tissue and lipotoxicity in the pathogenesis of type 2 diabetes. Curr Diab Rep 2010; 10: 306-315
4. Zhou YT, Grayburn P, Karim A, et al. Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci U S A 2000; 97: 1784-1789
5. Goldberg IJ, Trent CM, Schulze PC. Lipid metabolism and toxicity in the heart. Cell Metab 2012; 15: 805-812
6. Haemmerle G, Moustafa T, Woelkart G, et al. ATGL-mediated fat catabolism regulates cardiac mitochondrial function via PPAR-α and PGC-1. Nat Med 2011; 17: 1076-1085
7. Gehart H, Kumpf S, Ittner A, Ricci R. MAPK signalling in cellular metabolism: stress or wellness? EMBO Rep 2010; 11: 834-840
8. Liu Z, Cao W. p38 mitogen-activated protein kinase: a critical node linking insulin resistance and cardiovascular diseases in type 2 diabetes mellitus. Endocr Metab Immune Disord Drug Targets 2009; 9: 38-46
9. de Alvaro C, Teruel T, Hernandez R, Lorenzo M. Tumor necrosis factor alpha produces insulin resistance in skeletal muscle by activation of inhibitor kappaB kinase in a p38 MAPK-dependent manner. J Biol Chem 2004; 279: 17070-17078
10. Thandavarayan RA, Watanabe K, Ma M, et al. Dominant-negative p38alpha mitogen-activated protein kinase prevents cardiac apoptosis and remodeling after streptozotocin-induced diabetes mellitus. Am J Physiol Heart Circ Physiol 2009; 297:H911-H919
11. Ozcan L, Cristina de Souza J, Harari AA, Backs J, Olson EN, Tabas I. Activation of calcium/calmodulin-dependent protein kinase II in obesity mediates suppression of hepatic insulin signaling. Cell Metab 2013; 18: 803-815
12. Coulthard LR, White DE, Jones DL, McDermott MF, Burchill SA. p38(MAPK): stress responses from molecular mechanisms to therapeutics. Trends Mol Med 2009; 15: 369-379
13. Thandavarayan RA, Giridharan VV, Sari FR, et al. Depletion of 14-3-3 protein exacerbates cardiac oxidative stress, inflammation and remodeling process via modulation of MAPK/NF-κB signaling pathways after streptozotocin-induced diabetes mellitus. Cell Physiol Biochem 2011; 28: 911-922
14. Ozcan L, Xu X, Deng SX, et al. Treatment of obese insulin-resistant mice with an allosteric MAPKAPK2/3 inhibitor lowers blood glucose and improves insulin sensitivity. Diabetes 2015; 64: 3396-3405
15. Scharf M, Neef S, Freund R, et al. Mitogen-activated protein kinase-activated protein kinases 2 and 3 regulate SERCA2a expression and fiber type composition to modulate skeletal muscle and cardiomyocyte function. Mol Cell Biol 2013; 33: 2586-2602
16. Shiroto K, Otani H, Yamamoto F, Huang CK, Maulik N, Das DK. MK2-/- gene knockout mouse hearts carry anti-apoptotic signal and are resistant to ischemia reperfusion injury. J Mol Cell Cardiol 2005; 38: 93-97
17. Streicher JM, Ren S, Herschman H, Wang Y. MAPK-activated protein kinase-2 in cardiac hypertrophy and cyclooxygenase-2 regulation in heart. Circ Res 2010; 106: 1434-1443
18. Ruiz M, Gelinas R, Vaillant F, Lauzier B, Des Rosiers C. Metabolic tracing using stable isotope-labeled substrates and mass spectrometry in the perfused mouse heart. Methods Enzymol 2015; 561: 107-147
19. Kotlyarov A, Neininger A, Schubert C, et al. MAPKAP kinase 2 is essential for LPS-induced TNF-alpha biosynthesis. Nat Cell Biol 1999; 1: 94-97
20. Ayala JE, Samuel VT, Morton GJ, et al.; NIH Mouse Metabolic Phenotyping Center Consortium. Standard operating procedures for describing and performing metabolic tests of glucose homeostasis in mice. Dis Model Mech 2010; 3: 525-534
21. Khairallah M, Khairallah RJ, Young ME, et al. Sildenafil and cardiomyocyte-specific cGMP signaling prevent cardiomyopathic changes associated with dystrophin deficiency. Proc Natl Acad Sci USA 2008; 105: 7028-7033
22. Peng M, Fang X, Huang Y, et al. Separation and identification of under-ivatized plasma acylcarnitine isomers using liquid chromatography-tandem mass spectrometry for the differential diagnosis of organic acidemias and fatty acid oxidation defects. J Chromatogr A 2013; 1319: 97-106
23. Gélinas R, Thompson-Legault J, Bouchard B, et al. Prolonged QT interval and lipid alterations beyond β-oxidation in very long-chain acyl-CoA de-hydrogenase null mouse hearts. Am J Physiol Heart Circ Physiol 2011; 301: H813-H823
24. Kuwahara K, Wang Y, McAnally J, et al. TRPC6 fulfills a calcineurin signaling circuit during pathologic cardiac remodeling. J Clin Invest 2006; 116: 3114-3126
25. Belke DD, Dillmann WH. Altered cardiac calcium handling in diabetes. Curr Hypertens Rep 2004; 6: 424-429
26. Mekahli D, Bultynck G, Parys JB, De Smedt H, Missiaen L. Endoplasmic-reticulum calcium depletion and disease. Cold Spring Harb Perspect Biol 2011; 3: a004317
27. Zechner D, Thuerauf DJ, Hanford DS, McDonough PM, Glembotski CC. A role for the p38 mitogen-activated protein kinase pathway in myocardial cell growth, sarcomeric organization, and cardiac-specific gene expression. J Cell Biol 1997; 139: 115-127
28. Kotlyarov A, Yannoni Y, Fritz S, et al. Distinct cellular functions of MK2. Mol Cell Biol 2002; 22: 4827-4835
29. Houten SM, Wanders RJ. A general introduction to the biochemistry of mitochondrial fatty acid β-oxidation. J Inherit Metab Dis 2010; 33: 469-477
30. Schooneman MG, Vaz FM, Houten SM, Soeters MR. Acylcarnitines: reflecting or inflicting insulin resistance? Diabetes 2013; 62: 1-8
31. Vincent G, Bouchard B, Khairallah M, Des Rosiers C. Differential modulation of citrate synthesis and release by fatty acids in perfused working rat hearts. Am J Physiol Heart Circ Physiol 2004; 286:H257-H266
32. Chen ZC, Yu BC, Chen LJ, Cheng JT. Increase of peroxisome proliferator-activated receptor δ (PPARδ) by digoxin to improve lipid metabolism in the heart of diabetic rats. Horm Metab Res 2013; 45: 364-371
33. Kraemer FB, Shen WJ. Hormone-sensitive lipase: control of intracellular tri-(di-)acylglycerol and cholesteryl ester hydrolysis. J Lipid Res 2002; 43: 1585-1594
34. Kuramoto K, Sakai F, Yoshinori N, et al. Deficiency of a lipid droplet protein, perilipin 5, suppresses myocardial lipid accumulation, thereby preventing type 1 diabetes-induced heart malfunction. Mol Cell Biol 2014; 34: 2721-2731
35. Skovsø S. Modeling type 2 diabetes in rats using high fat diet and streptozotocin. J Diabetes Investig 2014; 5: 349-358
36. Bugger H, Abel ED. Molecular mechanisms of diabetic cardiomyopathy. Diabetologia 2014; 57: 660-671
37. Kranias EG, Hajjar RJ. Modulation of cardiac contractility by the phospholamban/SERCA2a regulatome. Circ Res 2012; 110: 1646-1660
38. Lukas SM, Kroe RR, Wildeson J, et al. Catalysis and function of the p38 alpha. MK2a signaling complex. Biochemistry 2004; 43: 9950-9960
39. Kaikkonen L, Magga J, Ronkainen VP, et al. p38α regulates SERCA2a function. J Mol Cell Cardiol 2014; 67: 86-93
40. Hammer S, Snel M, Lamb HJ, et al. Prolonged caloric restriction in obese patients with type 2 diabetes mellitus decreases myocardial triglyceride content and improves myocardial function. J Am Coll Cardiol 2008; 52: 1006-1012
41. Zierler KA, Jaeger D, Pollak NM, et al. Functional cardiac lipolysis in mice critically depends on comparative gene identification-58. J Biol Chem 2013; 288: 9892-9904
42. Pulinilkunnil T, Kienesberger PC, Nagendran J, et al. Myocardial adipose triglyceride lipase overexpression protects diabetic mice from the development of lipotoxic cardiomyopathy. Diabetes 2013; 62: 1464-1477
43. McGarry JD, Foster DW. Regulation of hepatic fatty acid oxidation and ketone body production. Annu Rev Biochem 1980; 49: 395-420
44. Kuo SC, Ku PM, Chen LJ, Niu HS, Cheng JT. Activation of receptors δ (PPARδ) by agonist (GW0742) may enhance lipid metabolism in heart both in vivo and in vitro. Horm Metab Res 2013; 45: 880-886
45. Duncan JG Mitochondrial dysfunction in diabetic cardiomyopathy. Biochim Biophys Acta 2011; 1813: 1351-1359
46. Shulman GI Ectopic fat in insulin resistance, dyslipidemia, and car-diometabolic disease. N Engl J Med 2014; 371: 1131-1141
47. Sam S, Mazzone T. Adipose tissue changes in obesity and the impact on metabolic function. Transl Res 2014; 164: 284-292
48. de Boer JF, Dikkers A, Jurdzinski A, et al. Mitogen-activated protein kinase-activated protein kinase 2 deficiency reduces insulin sensitivity in high-fat dietfed mice. PLoS One 2014; 9:e106300
49. Gaestel M. What goes up must come down: molecular basis of MAPKAP kinase 2/3-dependent regulation of the inflammatory response and its inhibition. Biol Chem 2013; 394: 1301-1315
50. Dulos J, Wijnands FP, van den Hurk-van Alebeek JA, et al. p38 inhibition and not MK2 inhibition enhances the secretion of chemokines from TNF-α activated rheumatoid arthritis fibroblast-like synoviocytes. Clin Exp Rheumatol 2013; 31: 515-525